Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • After giving...

    After giving exemption, NPPA asks Meril Life Sciences for MRP of its stent

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-08T15:29:59+05:30  |  Updated On 19 Dec 2022 2:42 PM IST
    After giving exemption, NPPA asks Meril Life Sciences for MRP of its stent

    New Delhi: Just days after giving exemption to cardiac stent maker Meril Life Sciences, the apex drug price regulator has asked the company to inform about the price that it is going to fix for the said product.

    Medical Dialogues team had earlier reported that Meril Life Sciences had applied to the NPPO with a price exemption application from the provisions of DPCO, 2013 under para 32 (ii) of the said order in respect of drug Coronary Stent namely "Sirolimus-Eluting Bioresorbable Vascular Scaffold System (MeRes100)" which was duly approved by the office of Central Drugs Standard Control Organisation (India) as 'new drug' under Rule 122(E) of the Drugs and Cosmetics Act and Rules thereunder, and patented by The Patent Office, India under the Patents Act, 1970 (Patent No. 296768 and Date of Grant: 14.05.2018).

    Read also: Should Next Gen DES Stents be removed from Price Cap- Govt Panel to Decide

    After series of deliberations and recording of objections by stakeholders, NPPA at its 73rd meeting dated 25.02.2020 noted that M/s Meril Life Sciences Pvt. Ltd meets the requirement of para 32(ii) of DPCO 2013 and decided that exemption may be granted to M/s Meril Life Sciences Pvt. Ltd under para 32(ii) of DPCO 2013 for their drug Coronary Stent namely "Sirolimus-Eluting Bioresorbable Vascular Scaffold System (MeRes100)

    Read also: Discrepancies in documents submitted by Meril Life Science for exempting MeRes100 from price cap; NPPA stalls decision

    With the decision, the said stent has now been an exemption from price capping for a period of five years from the date of the commencement of its commercial production in the country with the authorities now directing the company to inform about the price that it plans to fix for the stent

    "The company shall inform NPPA of the Maximum Retail Price fixed by the company in respect of above said formulation by issuing a price list in Form V under DPCO, 2013," NPPA stated in its recent order

    The order was issued by Prasenjit Das Asst. Director, NPPA.

    Read also: Meril Life Sciences Gets 5 Years Exemption From NPPA For Its MeRes100 Stent

    department-of-pharmaceuticalsnppanational-pharmaceuticals-pricing-authoritymeril-life-sciences

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok